背景:肺癌是一种常见的恶性肿瘤,具有很高的发病率和死亡率。氨基葡萄糖6-磷酸N-乙酰转移酶(GNPNAT1),它是己糖胺生物合成途径(HBP)中的关键酶,已被鉴定为转移相关基因,并在肺腺癌(LUAD)中上调。然而,GNPNAT1在LUAD转移中的作用及相关机制尚不清楚。
方法:我们分析了GNPNAT1在公共数据库中的表达,并通过免疫组织化学(IHC)证实了结果。基于癌症基因组图谱(TCGA)研究了GNPNAT1在LUAD中的生物学功能。通过使用表达数据(ESTIMATE)估计恶性肿瘤组织中的基质细胞和免疫细胞和通过估计RNA转录物的相对子集(CIBERSORT)R包来进行细胞类型鉴定,分析GNPNAT1与癌症免疫特征之间的相关性。GNPNAT1表达改变对LUAD细胞肿瘤发生的潜在机制,扩散,迁移,入侵,和转移进行了体外和体内探索。
结果:我们证明GNPNAT1表达在LUAD中显著增加,并且与患者的总生存期(OS)呈负相关。hsa-miR-1-3p和hsa-miR-26a-5p被鉴定为GNPNAT1的上游miRNA靶标。GNPNAT1与CD8T细胞的浸润水平有关,记忆激活的CD4T细胞,NK细胞静息,巨噬细胞M0,巨噬细胞M1,中性粒细胞,γδT细胞,和嗜酸性粒细胞,虽然它与记忆静息CD4T细胞呈负相关,调节性T细胞(Tregs),静息NK细胞,单核细胞,静息树突状细胞,和静止的肥大细胞。GNPNAT1敲低显著抑制增殖,迁移,入侵,上皮-间质转化(EMT)过程,和LUAD细胞的转移,而GNPNAT1的过表达显示出相反的作用。拯救实验显示Snai2敲低可逆转GNPNAT1诱导的LUAD细胞迁移,入侵,EMT。机械上,GNPNAT1通过抑制LUAD中Snai2的泛素化降解促进癌细胞转移。
结论:综合来看,这些数据表明GNPNAT1是LUAD患者的预后生物标志物.此外,GNPNAT1对于促进LUAD细胞的肿瘤发生和转移至关重要,并且可能是预防LUAD转移的潜在治疗靶标。
BACKGROUND: Lung cancer is a common malignant tumor with high morbidity and mortality rate. Glucosamine 6-phosphate N-acetyltransferase (GNPNAT1), which serves as a critical enzyme in hexosamine biosynthetic pathway (HBP), has been identified as a metastasis-associated gene and is upregulated in lung adenocarcinoma (
LUAD). However, the exact role and related mechanism of GNPNAT1 in
LUAD metastasis remain unknown.
METHODS: We analyzed the expression of GNPNAT1 in the public databases and confirmed the results by immunohistochemistry (IHC). The biological functions of GNPNAT1 in
LUAD were investigated based on The Cancer Genome Atlas (TCGA). Correlations between GNPNAT1 and cancer immune characteristics were analyzed via the Estimation of Stromal and Immune cells in Malignant Tumor tissues using Expression data (ESTIMATE) and Cell-type Identification by Estimating Relative Subsets of RNA Transcript (CIBERSORT) R package. The underlying mechanisms of altered GNPNAT1 expression on LUAD cell tumorigenesis, proliferation, migration, invasion, and metastasis were explored in vitro and in vivo.
RESULTS: We demonstrated that GNPNAT1 expression was significantly increased in LUAD and negatively associated with the overall survival (OS) of patients. hsa-miR-1-3p and hsa-miR-26a-5p were identified as upstream miRNA targets of GNPNAT1. GNPNAT1 was associated with the infiltration levels of CD8 T cells, memory-activated CD4 T cells, NK cells resting, macrophages M0, macrophages M1, neutrophils, gamma delta T cells, and eosinophils, while it was negatively correlated with memory-resting CD4 T cells, regulatory T cells (Tregs), resting NK cells, monocytes, resting dendritic cells, and resting mast cells. GNPNAT1 knockdown significantly inhibited proliferation, migration, invasion, epithelial-mesenchymal transition (EMT) process, and metastasis of LUAD cells, while overexpression of GNPNAT1 revealed the opposite effects. Rescue assay showed that Snai2 knockdown reversed GNPNAT1-induced
LUAD cells migration, invasion, and EMT. Mechanistically, GNPNAT1 promoted cancer cell metastasis via repressing ubiquitination degradation of Snai2 in LUAD.
CONCLUSIONS: Taken together, these data indicate that GNPNAT1 serves as a prognostic biomarker for LUAD patient. Additionally, GNPNAT1 is critical for promoting tumorigenesis and metastasis of LUAD cells and may be a potential therapeutic target for preventing
LUAD metastasis.